Reported Earlier, Theratechnologies Enters Definitive Agreement To Be Acquired By CB Biotechnology For $3.01 Per Share Plus Contingent Value Right
Author: Benzinga Newsdesk | July 03, 2025 01:16am
Offer of US$3.01 in cash plus one contingent value right for potential additional aggregate payments of up to US$1.19 per share
Upfront and total potential cash consideration represent respectively a 126% and 216% premium to Nasdaq closing price on date prior to announcement of Future Pak's initial non-binding proposal
Transaction with Future Pak represents culmination of sale process whereby Theratechnologies solicited interest from a number of potential counterparties
Board unanimously recommends that shareholders approve the transaction